Venus Viva FDA Approved for Ablation and Resurfacing

Venus Viva (Venus Concept) is now FDA approved for facial skin ablation and resurfacing. The minimally invasive NanoFractional Radio Frequency device delivers treatment via SmartScan technology. Providers can manually control ablation and coagulation for enhanced efficiency and patient comfort.

“The Venus Viva is the newest and most advanced radio frequency device on the market today. Our...

Articles

Venus Viva FDA Approved for Ablation and Resurfacing

Venus Viva (Venus Concept) is now FDA approved for facial skin ablation and...

James C. Grotting, MD, is the new president of the American Society for Aesthetic...

HUMIRA Receives Orphan Drug Designation for HS

The U.S. Food and Drug Administration (FDA) granted HUMIRA (adalimumab, AbbVie) orphan...

Botulinum Toxin Reduces Pain in Breast Reconstruction

Researchers conducted a pilot study in an effort to evaluate the potential role of...

Products

Age-Defying Serum

Rhonda Allison Peptide Primer blends resveratrol, rice peptide and CoQ10 to...

Comprehensive Antiaging Care

D•E•J face cream from Revision Skincare addresses the dermal-epidermal...

Lidocaine Added

Radiesse (+) with 0.3% lidocaine from Merz Aesthetics is now available in...

From the Inside Out

NovaHue Skin supplements from LycoRed contain Lyc-o-Derm, a proprietary...

Venus Viva FDA Approved for Ablation and Resurfacing

Venus Viva (Venus Concept) is now FDA approved for facial skin ablation and resurfacing. The minimally invasive NanoFractional Radio Frequency device delivers treatment via SmartScan technology. Providers can manually control ablation and coagulation for enhanced efficiency and patient comfort.

“The Venus Viva is the newest and most advanced radio frequency device on the market today. Our research showed great efficacy on a variety of different clinical indications including excellent results on facial wrinkles with no downtime and a very high level of patient comfort and satisfaction,” said Neil Sadick, MD, a board certified dermatologist from New York who participated in the clinical trials.

For more information, contact: 888.907.0115, www.venusconcept.com.

ASAPS and ASERF Name New Presidents

James C. Grotting, MD, is the new president of the American Society for Aesthetic Plastic Surgery (ASAPS). The results of the election were announced during The Aesthetic Meeting in Montreal on May 14-18.

Dr. Grotting is currently in private practice in Birmingham, Alabama. He is the past-president of the Southeastern Society of Plastic Surgeons, a clinical professor of plastic surgery at the University of Alabama at Birmingham, and a director and oral examiner for the American Board of Plastic Surgery.

“While it has been an honor and privilege to have served as ASAPS President for the past year, I can think of no better colleague to hand the reins to than Dr. Grotting,” said Michael Edwards, MD, immediate past president of ASAPS. “A noted lecturer, teacher, clinician and true thought leader in our specialty, he will use his educational experience and fair, balanced judgment to lead The Aesthetic Society in shaping the aesthetic landscape.”

The ASAPS research and education arm, the Aesthetic Surgery Education and Research Foundation (ASERF) also elected a new president: Neal R. Reisman, MD.

Dr. Reisman pioneered the split-muscle natural breast augmentation and short-scar mini-facelifts, and...

HUMIRA Receives Orphan Drug Designation for HS

The U.S. Food and Drug Administration (FDA) granted HUMIRA (adalimumab, AbbVie) orphan drug designation for the investigational treatment of moderate to severe hidradenitis suppurativa (HS)—a painful skin disease for which there is no known cure nor approved medication.

AbbVie's supplemental Biologic License Application seeking FDA approval for the use of HUMIRA for HS is currently under review.

“Patients living with hidradenitis suppurativa have limited treatment options and often experience severe, painful symptoms that can significantly impact their lives,” said Scott Brun, MD, AbbVie vice president, pharmaceutical development. “We are committed to researching treatment options to address the unmet needs of the dermatology community and we are pleased that the FDA has issued this designation and recognizes the treatment potential of HUMIRA.”

Photo copyright Getty Images.